LD-2 disclosure · 4th Quarter - Report
TONIX PHARMACEUTICALS, INC.
Client
- Name
- TONIX PHARMACEUTICALS, INC.
- Description
- biotechnology company--pharmaceuticals development and manufacturing
- Location
- New Jersey · United States of America
Registrant
- Description
- Government Relations
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesDisaster Planning/Emergencies
Proposed legislation on research and development into medical countermeasures for pandemic response and biosecurity in the PREVENT Pandemics Act S.3799 and the FY2023 Consolidated Appropriations Act (H.R. 2617).
LobbyistsSTEVEN A WOLFE
TargetedSENATE · HOUSE OF REPRESENTATIVES
Budget/Appropriations
Advocating for expanded funding for advanced development of COVID vaccines in the Labor-HHS-Education Appropriations Act for FY 2023 (H.R. 8295) and the Consolidated Appropriations Act, FY2023 (H.R. 2617). Advocating for expanded funding for Defense Department research and development on biodefense vaccines in the Defense Appropriations Act for FY 2023 (H.R. 8236) and the Consolidated Appropriations Act, FY2023 (H.R. 2617).
LobbyistsSTEVEN A WOLFE
TargetedSENATE · HOUSE OF REPRESENTATIVES
Defense
Advocating for increased funding for research and development on biodefense vaccines in the National Defense Authorization Act for FY2023 (H.R. 7900, S. 4543, H.R. 7776)
LobbyistsSTEVEN A WOLFE